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Abstract
Tumours of the anterior pituitary can manifest from all endocrine cell types but the 
mechanisms for determining their specification are not known. The Hippo kinase cascade 
is a crucial signalling pathway regulating growth and cell fate in numerous organs. There 
is mounting evidence implicating this in tumour formation, where it is emerging as an 
anti-cancer target. We previously demonstrated activity of the Hippo kinase cascade in 
the mouse pituitary and nuclear association of its effectors YAP/TAZ with SOX2-expressing 
pituitary stem cells. Here, we sought to investigate whether these components are 
expressed in the human pituitary and if they are deregulated in human pituitary tumours. 
Analysis of pathway components by immunofluorescence reveals pathway activity during 
normal human pituitary development and in the adult gland. Poorly differentiated 
pituitary tumours (null-cell adenomas, adamantinomatous craniopharyngiomas (ACPs) 
and papillary craniopharyngiomas (PCPs)), displayed enhanced expression of pathway 
effectors YAP/TAZ. In contrast, differentiated adenomas displayed lower or absent 
levels. Knockdown of the kinase-encoding Lats1 in GH3 rat mammosomatotropinoma 
cells suppressed Prl and Gh promoter activity following an increase in YAP/TAZ levels. 
In conclusion, we have demonstrated activity of the Hippo kinase cascade in the human 
pituitary and association of high YAP/TAZ with repression of the differentiated state both 
in vitro and in vivo. Characterisation of this pathway in pituitary tumours is of potential 
prognostic value, opening up putative avenues for treatments.
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Introduction
The Hippo kinase cascade is a crucial conserved signalling 
pathway regulating organ growth across diverse species, 
through the control of cell proliferation, apoptosis and 
differentiation during development (Zhao et  al. 2011). 
This phosphorylation cascade in mammals includes core 
kinases MST1/2 (a.k.a. STK3/4, orthologues of Drosophila 
Hippo) that activate large tumour suppressor homologs 
1 and 2 (LATS1/2), which in turn phosphorylate and 
inhibit the activation of transcriptional co-activators Yes-
associated protein (YAP), and WW domain-containing 
transcription factor (TAZ/WWTR1), the major effectors 
of the cascade. YAP/TAZ act as co-activators to TEAD 
transcription factors (TEA domain family members 1–4) 
(Zhao et  al. 2011). Nuclear YAP/TAZ are thus associated 
with low kinase activity and the promotion of growth, 
inhibition of apoptosis and the stem cell state, whilst 
cytoplasmic and phosphorylated YAP/TAZ are associated 
with active kinases and growth restriction. Deregulation 
of the mammalian Hippo signalling components has been 
implicated in the formation of tumours and cancers, with 
loss of MST1/2, LATS1/2, SAV or MOB1 resulting in the 
development of different tumour types in mouse models 
(Mo et al. 2014). Furthermore, elevated levels and nuclear 
localisation of YAP and/or TAZ have been reported in a 
wide array of human cancers including hepatocellular 
carcinoma, prostate cancer, colorectal carcinoma (CRC), 
non-small-cell lung cancer (NSCLC), ovarian cancer, clear 
cell renal cell carcinoma (ccRCC), pancreatic carcinoma, 
oesophageal squamous cell carcinoma, urothelial 
carcinoma of the bladder and skin basal cell carcinoma 
(Zanconato et al. 2016).
Pituitary tumours account for 10–15% of intracranial 
neoplasms (Molitch 2017). Although in general they are 
considered benign tumours, an aggressive or invasive 
behaviour is not uncommon (Di Ieva et al. 2014). Hormonal 
secreting (functioning) pituitary tumours are commonly 
detected due to the clinical syndromes caused by hormonal 
hypersecretion (Chanson et  al. 2015). Non-functioning 
subtypes are clinically challenging because they present at 
a later stage with local mass effects or hypopituitarism, as do 
craniopharyngiomas, both the adamantinomatous (ACP) 
and papillary (PCP) types. During the last years, progress 
has been made on the identification of mechanisms 
involved in anterior pituitary cell transformation and 
tumourigenesis; oncogene activation, tumour suppressor 
gene inactivation, epigenetic changes and microRNA 
deregulation have all been shown to contribute to the 
initiation of pituitary tumours (Marques & Korbonits 
2017). Recently, the isolation of cell subpopulations 
with stem-like characteristics was reported from human 
somatotropinomas and non-functioning pituitary 
adenomas, describing expression of stem cell markers 
(OCT4, SOX2, CD133, Nestin), sustained proliferation 
and a persistent undifferentiated compartment (Würth 
et  al. 2017). There is evidence for a role of the Hippo 
signalling cascade in pituitary gland pathophysiology. 
Mice deficient for Lats1 (Lats1−/−) present with hyperplasia 
of the anterior pituitary lobe, but reduced secretion of 
hormones such as LH, PRL and GH (St John et al. 1999). 
We recently mapped for the first time the activity of the 
Hippo-YAP/TAZ pathway in the murine pituitary during 
development and postnatal stages and revealed an 
association of active Hippo effectors (i.e. nuclear YAP/TAZ 
localisation) with the uncommitted pituitary stem cells 
expressing SOX2 (Lodge et al. 2016).
Considering the involvement of the Hippo kinase 
cascade in tumourigenesis, our observations in the 
murine gland prompted us to examine the expression 
patterns of YAP and TAZ in normal human pituitary 
and in pituitary tumours. Herein, we show for the first 
time that these proteins are expressed during human 
pituitary development as well as in the normal adult 
gland. YAP and TAZ were highly expressed in subsets of 
non-secreting pituitary tumours (null cell, ACP and PCP), 
but not in differentiated tumours. Activating this pathway 
in vitro by knocking down Lats1, decreased anterior 
pituitary hormone synthesis, further supporting a role 
for this cascade in repressing endocrine differentiation. 
Altogether, our data indicate a previously unappreciated 
involvement of the Hippo pathway in human pituitary 
differentiation, growth and tumour formation.
Materials and methods
Tissue specimens
All procedures performed were in accordance with the 
ethical standards of the institutional research committee 
(King’s College Research Ethics Committee, approval 
number LRS-15/16-2126) and with the 1964 Helsinki 
declaration and its later amendments or comparable 
ethical standards. Anonymised archival FFPE specimens 
of five ACP (Andoniadou et al. 2012) and six PCP (Haston 
et al. 2017) were identified in the local pathology archive, 
through the Childhood’s Cancer and Leukaemia Group 
Tissue Bank and BRAIN UK. The study also included 
ten null-cell pituitary tumours, 16 prolactinomas, one 
PRL-secreting carcinoma (Winkelmann et  al. 2002), 
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18 corticotropinomas and 10 somatotropinomas. 
Examples of confirmatory testing for these cohorts 
are provided in Supplementary Fig.  2 (see section on 
supplementary data given at the end of this article). 
Foetal pituitary tissue (two samples at 17 weeks and one 
sample at 14 weeks corrected gestational age) was accessed 
through the Human Developmental Biology Resource. 
Normal human pituitary glands were obtained from 
the School of Medicine, Lille, France from people who 
donated their body to science (two male, two female, ages 
77–89  years old); permission to use human tissues was 
obtained from the French Agency for Biomedical Research 
(Agence de la Biomédecine, Saint-Denis la Plaine, France, 
protocol no. PFS16-002). Ischaemia time until fixation 
ranged between 8 and 39 h. Pituitaries were fixed in 4% 
paraformaldehyde at 4°C for a minimum of 48 h before 
processing for paraffin embedding.
Immunofluorescence
Samples were dewaxed in Histo-Clear (National 
Diagnostics) twice for 10 min, followed by rehydration 
through a descending ethanol series. Antigen retrieval 
was carried out in citrate-based Declere unmasking 
solution (Cell Marque) in a Decloaking chamber NXGEN 
(Menarini Diagnostics) using the 110°C antigen retrieval 
protocol. Following blocking for 1 h in TNB-blocking 
buffer (0.1 M Tris–HCl pH7.5, 0.15 M NaCl, 0.5% Blocking 
Reagent (FP1020, Perkin Elmer)), samples were incubated 
overnight in primary antibodies at 4°C in TNB at the 
following dilutions: YAP (Cell Signaling Technology 
Cat. No. 4912, 1:1000), pYAP (S127) (Cell Signaling 
Technology Cat. No. 4911 1:1000), TAZ (Atlas Antibodies 
HPA007415, 1:2000) and SOX2 (Abcam ab97959, 1:2000). 
The following day, slides were washed in Tris–NaCl–Tween 
(TNT) buffer (0.1 M Tris–HCl, pH7.5, 0.15 M NaCl, 0.05% 
Tween-20) and incubated in species-specific biotinylated 
secondary antibodies (1:500, Abcam) diluted in TNB for 
1 h at room temperature. Following washes in TNT, slides 
were incubated in ABC solution (Vector Laboratories 
PK-6100) for 30 min in the dark and in TSA-Cy3 diluted in 
TSA Stock Solution (Perkin Elmer NEL760001) for 10 min 
at room temperature. Subsequently, slides were washed 
and incubated in Hoechst labelling solution for 30 min at 
room temperature. After a final wash, they were mounted 
with soft-set mounting medium (Vector Laboratories, 
H1000). Immunofluorescence staining was assessed as 
follows: Type A: high levels of both YAP/TAZ, frequent 
nuclear staining; Type B: robust levels of TAZ with 
frequent nuclear staining and moderate levels of YAP with 
occasional nuclear staining; Type C: moderate levels of 
YAP/TAZ, predominantly cytoplasmic, in over 50% of the 
tumour; Type D: low levels of YAP/TAZ, predominantly 
cytoplasmic, between 20 and 50% of tumour; Type E: 
absent YAP/TAZ staining or low levels in under 20% of 
the tumour.
Cell culture, transfection and luciferase assays
GH3 cells (American Type Culture Collection) were 
cultured in 10% foetal calf serum Dulbecco’s modified 
Eagle medium (DMEM) supplemented with 2.2 g/L 
NaHCO3, 10 mM HEPES, 2 nM Glutamine and 105 U/L 
penicillin-streptomycin. Cell culture materials were from 
Life Technologies, Nunc (Wiesbaden, Germany) and 
Sigma-Aldrich. Cells were transfected with SuperFect 
(Qiagen) following the manufacturer’s instructions. 
siRNA were against rat Lats1 (OriGene and Santa Cruz 
Biotechnology); a mix of scrambled non-specific siRNA 
was used as control. The Gh and Prl promoter reporter 
vectors have the proximal (_593) rat Gh promoter and rat 
Prl promoter respectively upstream to the luciferase gene 
(both kind gifts of A. Gutierrez-Hartmann, University 
of Colorado, Denver, CO, USA). After transfection, 
cells were left for 48 h in low serum (2% FCS) DMEM, 
before being treated and/or assayed. The transfection 
efficacy was determined by cotransfection with the 
RSV-β-gal construct and results are presented as 
luciferase:β-galactosidase activity ratio. Each experiment 
was done in triplicate.
Cell proliferation was determined 48 h after 
transfection using the WST-1 colorimetric assay (Roche 
Molecular Biochemicals) following the manufacturer’s 
instructions.
Immunoblotting
GH3 cells were lysed in ice-cold RIPA lysis buffer 
supplemented with protease and phosphatase 
inhibitor cocktail (Roche). Proteins were separated by 
polyacrylamide gel electrophoresis and blotted using 
standard procedures (BioRad). Primary antibodies were 
against LATS1 (C66B5, #3477), YAP/TAZ (D24E4, #8418) 
and phosphorylated pYAP(S127) (D9W2I, #13008) (all 
rabbit mAb, Cell Signaling) and β-actin (mouse mAb, 
Chemicon). Anti-rabbit or anti-mouse horseradish 
peroxidase-conjugated secondary antibodies were used 
(Cell Signaling) and signal was developed with enhanced 
chemiluminescent solution (Roche). Each experiment 
was carried out in duplicate.
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Results
YAP and TAZ are expressed in human foetal and 
adult pituitaries
To investigate the Hippo pathway activity in the human 
pituitary during development and adulthood, we 
determined the expression of its downstream effectors 
YAP and TAZ. In the human foetal pituitary at 17 weeks, 
high expression of both was observed in the posterior and 
anterior lobe within the epithelial remnants of Rathke’s 
pouch (marginal zone epithelium, MZE) that highly 
express the stem cell marker SOX2; the main body of 
the anterior lobe presented with moderate YAP and TAZ 
immunoreactivity (Fig. 1B). Both proteins mainly localised 
in the nucleus as well as the cytoplasm (arrowheads). 
The nuclear localisation was more prominent in the 
case of TAZ (arrowheads) throughout the MZE, similar 
to SOX2 expression. Nuclear immunoreactivity in the 
MZE was also observed for YAP, albeit to a lesser extent. 
The core Hippo kinases LATS1/2 phosphorylate YAP on 
serines S61, S109, S127, S164 and S381, leading to its 
inactivation through cytoplasmic retention (S127) and 
degradation (Zhao et  al. 2007, 2010). To determine if 
the kinases are active, we performed immunostaining 
Figure 1
YAP and TAZ are expressed in the human pituitary. (A) Haematoxylin and Eosin staining of sequential frontal sections of human foetal and adult 
pituitaries. Asterisks denote cysts between the anterior and posterior pituitary. (B) Frontal sections of foetal pituitaries at 17 weeks were stained for SOX2 
(pituitary stem/progenitor marker), total TAZ, total YAP and pYAP(S127) marking inactive YAP. Arrowheads indicate examples of cells with nuclear protein. 
(C) Localisation of SOX2, TAZ, YAP and pYAP proteins in the adult anterior pituitary. Arrowheads indicate examples of cells with nuclear protein, and 
examples of cytoplasmic localisation for pYAP in (B). AL, anterior lobe; MZE, marginal zone epithelium; Par, parenchyma; PL, posterior lobe. 
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against pYAP(S127) and observed strong cytoplasmic 
as well as nuclear localisation in both the epithelium 
and parenchyma (arrowheads), suggesting that LATS 
kinases are active during embryonic development. These 
observations were confirmed in further foetal pituitary 
samples at 17 and 14 weeks of gestation (Supplementary 
Fig. 1). To determine if expression of YAP and TAZ persists 
in the adult pituitary, we analysed immunoreactivities in 
adult pituitaries of advanced age (n = 4) (Fig. 1C). Strong 
nuclear TAZ staining persisted both in cells of the MZE and 
parenchyma, following the expression pattern of SOX2. 
YAP immunoreactivity was predominantly cytoplasmic 
in the MZE, whilst nuclear staining was occasionally 
observed in the parenchyma. Staining against pYAP(S127) 
persisted in the adult pituitary indicating the presence of 
an active Hippo cascade during adulthood. In summary, 
YAP and TAZ are expressed in the developing and adult 
human pituitary, where LATS kinases are active.
Expression of YAP and TAZ in pituitary tumours
We next sought to determine the expression patterns of 
YAP and TAZ in human pituitary tumours. In human 
craniopharyngiomas, which are composed mainly of 
non-endocrine cells, the expression of SOX2/SOX9 (both 
progenitor/stem cell markers) has been well documented 
in both the papillary type (PCP), harbouring MAPK 
pathway mutations as well as the adamantinomatous 
type (ACP) that harbour CTNNB1 mutations (encoding 
β-catenin) (Hölsken et al. 2014, Thimsen et al. 2017, Haston 
et al. 2017). Strong YAP and TAZ stainings were observed 
in all PCPs tested and were predominantly nuclear in 
the basal cells and suprabasal squamous epithelium 
(asterisks in Fig. 2A), described to robustly express SOX2 
(Haston et al. 2017) (Fig. 2A and Table 1). Strong nuclear 
staining for YAP and TAZ was observed in all five ACPs, 
both in whorl-like formations described to accumulate 
β-catenin (asterisks in Fig. 2B) as well as in the palisading 
epithelium (arrows in Fig. 2B). Null-cell pituitary tumours 
do not show immunoreactivity for any of the pituitary 
hormones, although there is evidence that in their 
majority, they express lineage-specific transcription 
factors (Mete & Lopes 2017, Nishioka & Inoshita 2018). 
YAP and TAZ expression was variable and was subdivided 
into three different groups based on a semiquantitative 
scoring system as described in the methods (Fig.  2C, 
Figure 2
Expression of YAP and TAZ in non-secreting pituitary tumours. (A) Representative immunostaining against TAZ, YAP and pYAP(S127) in samples of papillary 
craniopharyngioma (PCP). Arrowheads denote examples of nuclear staining; asterisks, the suprabasal squamous epithelium. (B) Representative 
immunostaining against TAZ, YAP and pYAP(S127) in samples of adamantinomatous craniopharyngioma (ACP). Arrowheads indicate nuclear staining; 
arrows, the palisading epithelium; asterisks, characteristic whorl-like cluster cells. (C) Immunostaining against TAZ, YAP and pYAP(127) on null cell pituitary 
adenomas, showing representative staining from tumours classified as Type A, B and C. Arrowheads indicate nuclear staining. Scale bars 100 µm.
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Table 1). Four out of ten null-cell tumours displayed high 
immunoreactivity consistent with Type A, three were 
identified as Type B and three as Type C. There was no 
obvious correlation of the immunohistochemical data 
to age at presentation, rate of recurrence, Ki-67 index or 
p53 levels, although the study cohort is low for this to be 
accurately determined (Table 2).
Altogether our data from normal pituitaries and 
pituitary tumours suggest that high levels of nuclear YAP 
/TAZ are associated with a more uncommitted state in the 
anterior pituitary, consistent with previous mouse data 
(Lodge et  al. 2016). To explore this hypothesis further, 
we extended our study to include 16 prolactinomas, the 
most common type of secreting pituitary tumours, 10 
somatotropinomas and 18 corticotropinomas. YAP and 
TAZ immunoreactivities were observed at much lower 
levels than in craniopharyngiomas and null-cell pituitary 
adenomas. Based on our semiquantitative scoring system, 
two types of staining were detected in prolactinomas: 
Type D, characterised by cytoplasmic YAP/TAZ in 20–50% 
of tumour cells, and Type E, characterised by the absence 
of staining or weak cytoplasmic in less than 20% of 
the tumour (Fig.  3A). In the majority of prolactinomas 
(11 out of 16), YAP/TAZ staining was classified as Type E, 
where most of the tissue was negative for YAP and TAZ. 
In corticotropinomas, staining ranged from Type B to 
Type D (Supplementary Fig. 3A) and in somatotropinomas 
from Type B to Type E (Supplementary Fig. 3B). Results are 
summarised in Table 1. To determine if YAP/TAZ become 
elevated in aggressive/invasive tumours, we analysed their 
expression in one PRL-secreting carcinoma. This tumour 
appeared entirely negative for both proteins (Fig.  3B, 
Region 1) and only one area included cells with nuclear, 
but not cytoplasmic TAZ staining and cytoplasmic YAP 
immunoreactivity, similar to adult normal anterior 
pituitary (Fig.  3B, Region 2). Therefore, YAP/TAZ levels 
are low in differentiated tumours, and in the single 
malignant prolactinoma sample analysed. In summary, 
robust expression levels and more abundant nuclear 
localisation of YAP/TAZ are seen in non-secreting tumour 
types, harbouring a less differentiated cellular component, 
compared to tumours composed of differentiated cells.
Table 1 Classification of YAP and TAZ staining in pituitary tumours.
Tumour type Classification Number TAZ YAP
Normal pituitary Type B 4 +++ n c ++ n c
PCP Type A 6 ++++ n c ++++ or +++ n c
ACP Type A 5 ++++ n c ++++ or +++ n c
Null-cell adenoma Type A 4 ++++ n c ++++ or +++ n c
Type B 4 +++ n c ++ n c
Type C 2 ++ or + c ++ or + c
Corticotropinoma Type B 5 +++ n c ++ n c
Type C 7 ++ or + c ++ or + c
Type D 6 + c + c
Somatotropinoma Type B 2 +++ n c ++ n c
Type C 2 ++ or + c ++ or + c
Type D 5 + c + c
Type E 1 − −
Prolactinoma Type D 11 + c + c
Type E 5 − −
−, negative staining; +, positive staining; ACP, adamantinomatous craniopharyngioma; c, cytoplasmic; n, nuclear; PCP, papillary craniopharyngioma.
Table 2 Related data for null-cell pituitary adenomas.
Sample Type Histology Ki-67 Notable characteristics p53 status Age at presentation Sex
Null1 A Null-cell adenoma 2–3% – 46 F
Null2 A Null-cell adenoma 3–5% 2–3% 27 F
Null3 A Null-cell adenoma 3–5% >1% 48 F
Null4 A Null-cell adenoma <3% – 36 F
Null5 B Null-cell adenoma 5–7% recurrence <1% 41 F
Null6 B Null-cell adenoma 2–3% – 73 F
Null7 B Null-cell adenoma 2–3% – 31 F
Null8 B Null-cell adenoma 1–2% – 49 F
Null9 C Null-cell adenoma <2% Necrotic areas – 48 M
Null10 C Null-cell adenoma 2.5% – 33 F
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Figure 3
Expression of YAP and TAZ in prolactin-secreting pituitary tumours. (A) Representative immunostaining against TAZ, YAP and pYAP(S127) in prolactinoma 
samples. Based on the staining patterns tumours were classified as Type D or Type E. (B) Expression of TAZ and YAP in two regions of a prolactin-secreting 
carcinoma. Scale bars 100 µm. 
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Lats1 knockdown reduces Gh and Prl promoter 
activity in GH3 cells in vitro
Our observations of a robust decrease or loss of YAP/TAZ 
in hormone-secreting pituitary tumours, compared to 
normal pituitary and non-secreting tumours, suggest a role 
for the Hippo kinases in promoting a hormone-secreting 
phenotype and/or repressing a progenitor/stem-like state. 
To this end, employing RNA interference, we inhibited 
LATS1, since it directly phosphorylates and marks YAP 
and TAZ for cytoplasmic retention and degradation. 
Knockdown of Lats1 in rat mammosomatotropinoma 
GH3 cells reduced YAP phosphorylation at S127 and 
increased YAP and TAZ protein levels (Fig. 4A). This was 
accompanied by significant suppression of basal Gh and Prl 
promoter activity (Fig. 4B). Lats1 inhibition also reduced 
activation of the Gh promoter following stimulation with 
forskolin compared to scrambled siRNA control (Fig. 4C). 
Lats1 inhibition did not affect GH3 cell proliferation 
(Fig. 4D). These in vitro findings indicate that deregulation 
of the Hippo pathway may repress pituitary hormone 
synthesis and compromise the pituitary cell response to 
physiological hormonal stimuli.
Discussion
Initially described in Drosophila, the Hippo pathway is 
now recognised as one of the most conserved molecular 
pathway in all metazoans, which is highly involved in fine-
tuning of organ size through inhibition of proliferation 
and promotion of differentiation and cell death (Yu 
et  al. 2015) with a contribution to tumourigenesis and 
cancer development (Mo et al. 2014). The present study 
demonstrates for the first time the expression patterns of 
two major downstream effectors of the Hippo pathway, 
YAP and TAZ, in the foetal and adult normal pituitary 
gland and provides evidence of Hippo pathway activity 
during embryonic development that persists into 
adulthood. Interestingly, the YAP/TAZ expression pattern 
is reminiscent of SOX2 in pituitary stem/progenitor 
Figure 4
LATS1 inhibition with RNA interference 
suppresses the promoter activities of anterior 
pituitary hormones. (A) GH3 cells were 
transfected with a scrambled siRNA (control) or 
four different siRNA against rat Lats1 for 48 h. 
Immunoblot shows the knockdown efficacy and 
the impact of decreased LATS1 protein on YAP 
phosphorylation at Ser127 and total YAP and TAZ 
protein levels. (B) Effect of Lats1 knockdown on 
basal Prl and Gh promoter activity. Data are 
luciferase to β-galactosidase ratio, 
means ± standard deviation of three experiments 
(each in triplicate) presented as percentage of 
scrambled control. RLA, relative luciferase 
activity. *P < 0.05 to scrambled vehicle control.  
(C) Effect of Lats1 knockdown on forskolin-induced 
(10 µM, 6 h treatment) Gh promoter activity. Data 
are means ± standard deviation of three 
triplicates and presented as percentage of 
scrambled vehicle control. *P < 0.05 and 
***P < 0.001 vs scrambled vehicle control, 
#P < 0.05 vs siLats1 vehicle control. Veh, vehicle – the 
carrier in which forskolin was diluted. (D) Lats1 
knockdown does not affect cell proliferation 
(WST-1 colorimetric assay). Data are absorbance 
at OD450nm presented as percentage of 
scrambled siRNA control.
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cells recapitulating our previous findings in mice and 
indicating a potential link of the Hippo pathway to the 
stem/progenitor cell state (Lodge et al. 2016).
We investigated the expression of YAP/TAZ in three 
types of non-secreting/non-differentiated pituitary 
tumours: null-cell adenomas, ACPs and PCPs. YAP and 
TAZ were highly expressed in all ACP and PCP tumours. 
The expression pattern was nuclear and occasionally 
cytoplasmic in craniopharyngiomas that harbour known 
genetic mutations in CTNNB1 or BRAF and was located 
to well-characterised tumour compartments known 
to express progenitor markers. ACP tumourigenesis is 
mainly driven by mutations in the CTNNB1 gene that 
encodes for β-catenin, the central regulator of the WNT 
pathway (Sekine et  al. 2002). Gain-of-function alleles 
of BRAF activate the RAS-RAF-MEK-ERK pathway and 
may drive tumourigenesis in PCPs, which appear almost 
exclusively in adults (Brastianos et al. 2014, Larkin et al 
2014). In support of this, a mouse model overexpressing 
BRAF V600E in mouse pituitary precursors leads to 
increased proliferation of SOX2 stem cells and a block 
in differentiation (Haston et al. 2017). Interestingly, both 
pathways were described to crosstalk with the Hippo 
signalling cascade. YAP forms a transcriptional complex 
with β-catenin that is required for tumour transformation 
and survival (Rosenbluh et al. 2012). When core Hippo 
kinases are active, YAP/TAZ are degraded or sequestered 
in the cytosol where they limit WNT-β-catenin signalling 
(Varelas et  al. 2010). In contrast, WNT activation 
induces YAP/TAZ translocation to the nucleus and 
target activation (Attisano & Wrana 2013, Azzolin et al. 
2014). Similarly, RAS signalling activates YAP, and there 
is evidence for involvement of YAP in tumour resistance 
to pharmacological RAF-MEK inhibition (Reddy & Irvine 
2013, Lin et al. 2015, You et al. 2015).
YAP and TAZ were also highly expressed in null-
cell pituitary tumours, but at variable levels. Similar to 
craniopharyngiomas, they also often displayed strong 
nuclear staining. There is mounting evidence that TAZ 
and YAP nuclear localisation correlates with metastatic 
potential, low response to treatment and worse patient 
outcome in several solid tumours (Zanconato et al. 2016). 
The relatively small number of cases did not allow us 
to correlate the pattern of staining with histological or 
clinical data but also, recurrence may happen even after 
years of remission. Based on the recent WHO classification 
for pituitary adenomas, clinical aggressiveness is assessed 
by several clinical parameters such as tumour invasion 
(by MRI studies and/or intraoperative impression), in 
addition to mitotic count and Ki-67 index (Lopes 2017). 
Whether YAP/TAZ may directly promote an oncogenic 
phenotype in the pituitary through activation of genes 
involved in proliferation/survival/invasion directly or 
secondary to other genetic defects like the ones found in 
ACP and PCP is an intriguing possibility that remains to 
be explored.
In contrast to the majority of the non-differentiated 
tumours that often displayed strong nuclear staining, YAP 
/TAZ expression in the hormone-secreting prolactinomas 
was very low or completely absent, suggesting that in the 
human pituitary YAP/TAZ expression may be associated 
with a shift from high to low secretory potential and 
therefore a less differentiated state. Indeed, our in vitro 
model showed that increasing YAP and TAZ expression 
in lactosomatotroph GH3 cells, by knocking down their 
upstream regulator Lats1, dramatically reduces PRL as well 
as GH production without affecting cell proliferation. 
Interestingly in the case of GH, the effect is prominent 
also after cAMP/PKA stimulation with forskolin. These 
data reflect the observations in the Lats1−/− mice, which 
presented with low PRL and GH levels despite their 
hyperplastic pituitaries (St John et  al. 1999). YAP/TAZ 
were shown to repress the differentiated state in other 
tissues (Lee et al. 2016, Yi et al. 2016, Cotton et al. 2017). 
Our data further support this notion and suggest that 
high levels of YAP/TAZ are associated with repression of 
hormone production and therefore a non-differentiated 
/progenitor state.
Treatment of pituitary tumours primarily relies 
on reducing hormone hypersecretion and its effects, 
decreasing the tumour mass and treating for any hormone 
deficiencies resulting from damage of normal pituitary 
tissue. Hippo signalling components and particularly 
YAP/TAZ have recently become attractive targets for 
new anti-cancer treatments (Johnson & Halder 2013, 
Nakatani et al. 2016). Our finding of increased expression 
of YAP/TAZ in non-secreting pituitary tumours reveals a 
previously unsuspected pathogenetic mechanism. Better 
understanding and targeting of the Hippo signalling 
cascade could introduce novel improved treatments for 
these intriguing and hard to manage tumours.
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